Bayer Healthcare, Onxy Pharma gets USFDA OK for Stivarga tablets

By Admin
Bayer HealthCare and Onyx Pharmaceuticals Inc said that U.S. Food and Drug Administration has approved Bayers Stivarga ®(regorafenib) tablets to tr...

Bayer HealthCare and Onyx Pharmaceuticals Inc said that U.S. Food and Drug Administration has approved Bayer’s Stivarga ® (regorafenib) tablets to treat patients with metastatic colorectal cancer.

The approval for Bayer’s Stivarga tablets is based on the results from the Phase III study which demonstrates improvement in the overall survival and progression-free survival.

Stivarga is a Bayer compound developed by Bayer, the company said. Last year, Bayer signed a deal with Onyx Pharmaceuticals, Inc under which Onyx will get a royalty on any future global net sales of Stivarga in oncology. 

Both these companies will jointly promote Stivarga in the United States. “The approval of Stivarga reflects Bayer’s commitment to confronting the challenges of difficult-to-treat cancers,” said, Pamela A. Cyrus, MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  “Patients with metastatic colorectal cancer whose disease has returned after treatment will now have a new option that has been shown to prolong survival and keep the cancer from progressing.," Pamela said.

Stivarga is indicated to treat patients with mCRC  who have been earlier treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

The frequently observed adverse drug reactions in patients receiving Stivarga are asthenia, decreased appetite and food intake, hand-foot-skin reaction, erthrodysesthesia, diarrhea, mucositis, weight loss, infection, hypertension and dysphonia.  

Most serious adverse drug reaction in patients receiving Stivarga includes hepatotoxicity, hemorrhage and gastrointestinal perforation.

Bayer HealthCare is the U.S.-based pharmaceuticals business of Bayer Healthcare LLC, a subsidiary of Bayer AG. It is also the world’s innovative companies in the healthcare and medical products industry. 


Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI


Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI